RxDoctor Payments Data

Katherine Krevolin

Family · Hamden, CTNPI 1871149153

Payments from drug & device makers

$4,352in general payments, 2019–2025

Across 185 payments — averaging $23.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$449
  • Ardelyx, Inc.$366
  • Gilead$296
  • Johnson & Johnson$244
  • QOL Medical, LLC$243
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$4,352100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,352 in reported general payments places this provider in the 90th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Medicare billing

Part B allowed, 2024
$12,413
Medicare patients
140
Services billed
162

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide52$52,826
XifaxanRifaximin11$24,737
Dexlansoprazole DrDexlansoprazole36$14,379
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates133$8,671
MovantikNaloxegol Oxalate15$7,899
SutabSod Sulf/Pot Chloride/Mag Sulf29$4,696
ClenpiqSod Picosulf/Mag Ox/Citric Ac27$4,691
Ondansetron Hcl36$3,646
Budesonide EcBudesonide11$3,382
Omeprazole188$2,735
Pantoprazole Sodium138$2,115
Lubiprostone22$1,746
Famotidine100$1,616
Esomeprazole Magnesium35$1,597
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C11$1,543

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,471$52,82652 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu$159$26,28122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,596 family providers in Connecticut.

Other family in Hamden

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →